NCCN 2022 Nursing Program: Advancing Oncology Nursing

March 30, 2022

This program provides oncology nurses with comprehensive and clinically relevant information to optimize clinical care and patient education. The diverse program content addresses the complexities of care for patients with cancer and the dynamic role of the oncology nurse across the continuum of care. This is an exciting opportunity for oncology nurses to gain practical knowledge from leading clinical nursing experts and network with their peers in an engaging and interactive environment.

Target Audience

This program is designed to meet the educational needs of oncology nurses who manage patients with cancer.

Learning Objectives

Following this program, participants should be able to:

Overall Learning Objectives
•   Evaluate advances in the management of patients with cancer and key updates in the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) and apply appropriate treatment and supportive care strategies to optimize patient education and care.
•   Review issues related to Emerging Treatment Landscape of Targeted Therapies in Hematologic Malignancies; Desensitization Protocols in the Outpatient Setting; Updates in the Treatment of Lymphoma; Toxicities of CAR T-cell Therapy: Beyond CRS and Neurotoxicity; Updates in the Treatment of CNS Cancers; Communicating an Adult Diagnosis of Cancer to Children; and, Developing an Oncofertility Program to Pre-Pubertal, Adolescent and Young Adult Patients.

Emerging Treatment Landscape of Targeted Therapies in Hematologic Malignancies
•   Discuss the current targeting pathways and therapies used for hematologic malignancies.
•   Review common challenges faced while using targeted therapies in hematologic malignancies.
•   Provide examples of future research in targeted therapy for hematologic malignancies..

Desensitization Protocols in the Outpatient Setting
•   Discuss the treatment of chronic lymphocytic leukemia (CLL) in the 2nd and 3rd line setting.
•   Discuss treatment of follicular lymphoma (FL) for 2nd/3rd line treatment based on disease burden/performance status.
•   Discuss emerging therapies for mantle cell lymphoma (MCL), including immunotherapy and cellular therapy.

Updates in the Treatment of Lymphoma
•   Discuss the treatment of chronic lymphocytic leukemia (CLL) in the 2nd and 3rd line setting.
•   Discuss treatment of follicular lymphoma (FL) for 2nd/3rd line treatment based on disease burden/performance status.
•   Discuss emerging therapies for mantle cell lymphoma (MCL), including immunotherapy and cellular therapy.

Toxicities of CAR T-cell Therapy: Beyond CRS and Neurotoxicity
•   Provide an overview of the role of CAR-T therapy in various cancer types.
•   Discuss long-term side effects of CAR-T therapy, including macrophage activation syndrome, B-cell aplasia, and prolonged cytopenia.
•   Discuss management of long-term effects of CAR-T therapy, presenting evidence-based intervention.

Updates in the Treatment of CNS Cancers
•   Define malignant tumors of the central nervous system with a focus on primary tumors of the brain.
•   Evaluate current clinical trials and optimal treatments for primary and secondary brain tumors.
•   Discuss associated symptom management and prognosis of primary brain tumors.
•   Examine practices in supportive care for patients, caregivers, and nurses.

Communicating an Adult Diagnosis of Cancer to Children
•   Describe the importance of involving children in the communication of the parent’s diagnosis.
•   Provide examples of strategies to communicate a diagnosis of cancer to children and resources available to aid in the conversation.
•   Discuss opportunities to involve other members of the child’s multidisciplinary team (e.g., teachers, clergy, school counselor).

Developing an Oncofertility Program for Pre-Pubertal, Adolescent and Young Adult Patients
•   Identify risk factors for treatment-related infertility in pre-pubertal, adolescent, and young adult (AYA) oncology patients.
•   Describe fertility preservation options for pre-pubertal and pubertal males and females.
•   Identify members of a successful multidisciplinary Oncofertility Team and key points of clinical practice.
•   Identify potential barriers of proper fertility support.
•   Highlight the overall importance of proactive Oncofertility care to long-term survivorship.

Additional information
Supporters: 

This activity is supported by educational grants from:

  • AstraZeneca
  • Epizyme Inc.
  • Genentech, a member of the Roche Group
  • Novartis
  • Pharmacyclics LLC, an AbbVie Company and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC
  • Pfizer Inc.
Course summary
Available credit: 
  • 5.50 ANCC contact hours
    • 3.00 ANCC Pharmacology Contact Hours
  • 5.50 Participation
Course opens: 
03/29/2022
Course expires: 
08/31/2022
Event starts: 
03/30/2022 - 9:30am EDT
Event ends: 
03/30/2022 - 4:30pm EDT
Cost:
$0.00
Add to calendar: 

NCCN Continuing Education Disclosure Policy

It is the policy of NCCN that all planners, faculty, moderators, authors, reviewers and anyone involved in the planning and delivery of NCCN continuing education activities are expected to disclose ALL financial relationships they have had in the past 24 months with ineligible companies. The ACCME Standards for Integrity and Independence require that individuals who refuse to provide this information will be disqualified from involvement in the planning and implementation of accredited continuing education presented by NCCN. NCCN identifies, mitigates, and discloses to learners all relevant financial relationships.

In addition, all content has been reviewed to ensure education promotes safe, effective patient care and does not promote the products or services of an ineligible company. Content, including any presentation of therapeutic options, is fair, balanced, evidence-based, scientifically accurate, and free of commercial bias and marketing. 

Definitions 

Ineligible Company: An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. 

Relevant Financial Relationships: Financial relationships of any dollar amount occurring within the past 24 months are defined as relevant if the educational content an individual can control is related to the business lines or products of an ineligible company. There is no minimum financial threshold. We ask for disclosure of ALL financial relationships with ineligible companies, regardless of the amount and regardless of the potential relevance of each relationship to the education.

Faculty Disclaimers

All faculty for this continuing education activity are competent in the subject matter and qualified by experience, training, and/or preparation for the tasks and methods of delivery.

Faculty presentations may include discussion of off-label use. Faculty will disclose that the use in question is not currently approved by the FDA per the product labeling or marketing.

Faculty Disclosures

Presenting Faculty

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Emely Alfaro, RN, MSN, CNS, OCN
Lynne Brophy, MSN, PMGT-BC, APRN-CNS, AOCN
Katherine L. Byar, MSN, APRN-BC, BMTCN
Claire Carlson, RN, BSN
Linda McKenna, AGACNP-BC, ANP-BC, CNS, CCRN-CMC
Jessica Shelly, CRNP, APRN
Tia Wheatley, DNP, RN, AOCNS, BMTCN, EBP-C

Moderators

The faculty listed below have no relevant financial relationship(s) with ineligible companies to disclose.

Colleen Erb, MSN, RN, AOCNP
Kristina M. Gregory, RN, MSN, OCN
Amanda E. Visnick, RN, BSN, OCN

The faculty listed below have the following relevant financial relationship(s) with ineligible companies to disclose.  All of the relevant financial relationships listed for these individuals have been mitigated.

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

NCCN Staff Disclosures 

The planners listed below have the following relevant financial relationship(s) with ineligible companies to disclose. All of the relevant financial relationships listed for these individuals have been mitigated.

Crystal Denlinger, MD, FACP
Agios, Inc.: Grant/Research Support
Amgen Inc.: Grant/Research Support
Astellas Pharma US, Inc.: Scientific Advisor
AstraZeneca Pharmaceuticals LP: Grant/Research Support
BeiGene: Scientific Advisor; Grant/Research Support
Bristol-Myers Squibb Company: Scientific Advisor; Grant/Research Support
Eli Lilly and Company: Grant/Research Support
Exelixis Inc.: Scientific Advisor; Grant/Research Support
Genmab: Grant/Research Support
MacroGenics: Grant/Research Support
MedImmune Inc: Grant/Research Support
Merck & Co., Inc.: Scientific Advisor
sanofi-aventis U.S.: Grant/Research Support
Taiho Pharmaceutials Co., Ltd.: Scientific Advisor
Zymeworks: Scientific Advisor; Grant/Research Support

Samantha L. Tamburro, RN, BSN, CPON
Flatiron Health, Inc.: Salary

None of the other planners for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

In support of improving patient care, National Comprehensive Cancer Network (NCCN) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurses
NCCN designates this educational activity for a maximum of 5.5 contact hours.

This program offers 3 pharmacotherapeutic contact hours for nurses. Eligible sessions are listed below:

  • Emerging Treatment Landscape of Targeted Therapies in Hematologic Malignancies
  • Updates in the Treatment of Lymphoma
  • Updates in the Treatment of CNS Cancers
  • Toxicities of CAR T-cell Therapy: Beyond CRS and Neurotoxicity

Available Credit

  • 5.50 ANCC contact hours
    • 3.00 ANCC Pharmacology Contact Hours
  • 5.50 Participation

Price

Cost:
$0.00
Please login or register to take this course.

 

Click the Take Course button to start the credit claiming process.
You must be logged in with the same email address used for program registration.

CE credit should be claimed for the program as a whole, not session by session. You may claim credit for the program only one time. When calculating your total credits, you should take into account all of the sessions you viewed either live or via recording. (Please note that you have access to all of the session recordings for 60 days following the live program.) 

Required Hardware/software

To complete this activity, users will need:

  • A device with an Internet connection and sound playback capability
    • One of the two latest versions of Google Chrome, Mozilla Firefox, or Safari
    • Internet Explorer is no longer supported
  • Adobe Reader or other PDF reader software for certificate viewing/printing